metricas
covid
Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular
Toda la web
35.º Congreso de la Sociedad Española de Medicina Nuclear e Imagen Molecular Neurociencias
Información de la revista

Congreso

Contenidos del congreso
Congreso
35.º Congreso de la Sociedad Española de Medicina Nuclear e Imagen Molecular
Burgos, 17 - 19 junio 2015
Listado de sesiones
Comunicación
21. Neurociencias
Texto completo

0 - PROGNOSTIC VALUE OF 18F-FLORBETAPIR SCAN: A 36-MONTH FOLLOW UP ANALYSIS USING ADNI DATA

G. Dell’Agnello1, M. Lu2, M.J. Pontecorvo2, A. Siderowf2, A.D. Joshi2, M.D. Devous2 and M.A. Mintun2

1Eli Lilly and Company. Indianapolis. IN. USA. 2Avid Radiopharmaceuticals. Inc. Philadelphia. PA. USA.

Objective: The Alzheimer's Disease Neuroimaging Initiative (ADNI) provides a unique opportunity to investigate the relationship between β-amyloid neuropathology and patients’ long-term cognitive function change. We examined baseline 18F-florbetapir PET amyloid imaging status and 36-months change from baseline in cognitive performance in subjects with mild cognitive impairment (MCI).

Material and methods: All ADNI subjects who underwent PET-imaging with 18F-florbetapir and had a clinical diagnosis of MCI at the visit closest to florbetapir imaging, were included. β-amyloid deposition was measured by florbetapir standard uptake value ratio (SUVR), and dichotomized as Aβ+ (SUVR > 1.1) or Aβ– (SUVR ≤ 1.1). The change of cognitive scores including ADAS11, MMSE and CDR sum of boxes (CDR-SB) were evaluated every 6 months. Mixed-effect Model Repeated Measures (MMRM) was applied to detect the difference between Aβ+ and Aβ– subjects’ cognitive score change from baseline, adjusting for baseline age and cognitive scores. Clinically significant cognitive change (4 point decline on the ADAS 11) was also evaluated using a multivariate-logistic-regression-model with general estimating equation (GEE) to account for within-subjects correlation. Marginal Odds Ratio was used to evaluate the risk difference for a clinically significant cognitive change among Aβ+ participants vs Aβ– participants.

Result: Of 478 MCI-subjects who had at least one florbetapir scan, 153 had a cognitive evaluation at 36-month follow up. Of those, 79 were Aβ– and 74 Aβ+. At 36-month visit, the Aβ+ vs Aβ– group score changed from baseline (LS means 4.03 vs 0.26 for ADAS 11; -2.61 vs-0.40 for MMSE; 1.53 vs -0.11 for CDR-SB [p < 0.0001 all comparisons]). GEE analysis on clinically significant cognitive change showed a marginal Odds Ratio = 2.18 (95%CI: 1.47–3.21) for Aβ+ vs Aβ– groups.

Conclusions: MCI subjects with higher β-amyloid deposition, had greater deterioration in cognitive function over the 36-month follow up, while subjects with no β-amyloid accumulation tended to be stable on these measurements. This finding is consistent with previously published studies.

Listado de sesiones

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos